2637 — Fujian Haixi Pharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00- HK$13.91bn
- HK$14.03bn
- CNY582.36m
Annual income statement for Fujian Haixi Pharmaceuticals Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 212 | 317 | 467 | 582 |
| Cost of Revenue | ||||
| Gross Profit | 172 | 264 | 387 | 486 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 132 | 196 | 341 | 398 |
| Operating Profit | 80.4 | 120 | 125 | 184 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 73.8 | 133 | 149 | 198 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 69 | 117 | 136 | 177 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 69 | 117 | 136 | 177 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 69 | 117 | 136 | 177 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.877 | 1.49 | 1.82 | 2.65 |